STOCK TITAN

Exscientia to Present at Upcoming Investor Conferences in September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
Exscientia plc to participate in investor conferences in September 2023
Positive
  • None.
Negative
  • None.

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in September:

  • 2023 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2023, at 3:45 p.m. EDT (8:45 p.m. BST) in Boston, Massachusetts
  • Morgan Stanley Global Healthcare Conference 2023. Formal presentation on Tuesday, September 12, 2023, at 8:10 a.m. EDT (1:10 p.m. BST) in New York, NY

Live webcasts will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Investor Relations Contact:

Sara Sherman

investors@exscientia.ai

Media Contact:

Oliver Stohlmann

media@exscientia.ai

Source: Exscientia plc

Exscientia plc

NASDAQ:EXAI

EXAI Rankings

EXAI Latest News

EXAI Stock Data

597.75M
92.58M
26.47%
26.2%
3.45%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Oxford

About EXAI

at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.